Adherence, Cognition and Behavioral Outcomes in Multiple Sclerosis (MS) Patients on Dimethyl Fumarate – 12-Month Results of a Longitudinal Registry Study in German MS Practice Centers (TREAT)

Scholl S^{1,4*}, Thaler L^{1,4*}, Roßnagel F², Schlegel S³, Braisch U³, Lehr L⁴, Sedlmeier R⁵, Schmid B⁵, Freudensprung U⁶, Wettmarshausen C⁵, Muche R³, Bergmann A², Schreiber H^{2,4} *equally contributed

¹Ulm University, Medical Faculty, Helmholzstraße 16, Ulm (Germany); ³Ulm University, Institute of Epidemiology and Medical Biometry, Ulm (Germany); ³Ulm University, Institute of Epidemiology and Medical Biometry, Ulm (Germany); ³Ulm University, Institute of Epidemiology and Medical Biometry, Ulm (Germany); ⁴Neuropoint Academy, Ulm (Germany); ³Ulm University, Institute of Epidemiology and Medical Biometry, Ulm (Germany); ⁴Neuropoint Academy, Ulm (Germany); ⁴Neuropoint

Conclusions

- DMF is effective in stabilizing clinical, cognitive and behavioral parameters in early **RRMS-patients.**
- Behavioral factors, gender and pre-treatment issues emerged as putative predictors for non-adherence. Multiple regression analyses considering collinearity will be performed in the forthcoming final analysis.

Introduction

• NeuroTransData is a German network of currently 72 neurology practice centers using its MS database (n = 22,000 MS patients) to collect "real world" data about longitudinal evolution and treatment in MS.

Objectives

- (1) Assessment of adherence, disability, cognition and patient-reported outcomes (PRO) in relapsing-remitting MS (RRMS) patients on dimethyl fumarate DMF as first-line treatment or switching from other disease-modifying therapies.
- (2) Identification of relevant factors for nonadherence (discontinuation of study or DMF intake)

Methods

- 12 months interim analysis (T12) of a 2-year prospective, multicenter, open-label registry study with assessments at baseline (TO) and at T3, T6, T9, T12, T18 and T24 months.
- Demographic baseline charactaristics of the study population (12 months analysis set) are shown in Table 1.

BASELINE (TO)	тз	Т6	Т9	T12	T18	T24
4 2014						

- At T12, 721 RRMS patients treated with DMF (mean age 40.9 years, 72.4% female, 27.6%) male, median EDSS 2.0) entered analysis.
- Outcomes: adherence (yes/no) and time to non-adherence, disability, cognition and PROs representing treatment/life satisfaction, depression, anxiety, fatigue, QoL, disease coping and personality.
- Descriptive analysis and univariate regression models (logistic and Cox) were used to assess the factors associated with adherence.

Results

(12 months analysis set)

Variable (SD = standard deviation; min = minimum; max = maximum)		Patient number
Sex	male: 27.6%	199
Sex	female: 72.4%	522
Age (years), mean (SD)	40.9 (10.7)	721
BMI, mean (SD)	25.0 (5,2)	648
	none: 4.0%	29
Professional achievement	apprenticeship: 72.4%	522
	university degree: 23.6%	170
EDSS, median (min, max)	2.0 (0.0, 7.5)	704
Number of relapses (last 12 months), median (min, max)	0.0 (0.0, 5.0)	721
Time since diagnosis (years), median (min,	5.7 (0.0, 33.0)	721

(years), meuran (min, max)

• DMF is well tolerated with 73.2% patients remaining on constant treatment during the first year. Discontinuations (of treatment or study) primarily occured during the first months of treatment.

• All clinical, behavioral and cognitive parameters remained stable during the first 12 months of DMF treatment (Table 2)

• By T12, 26.8 % (193/721) of patients reported to be non-adherent. Women were more likely to be non-adherent (OR 1.9, HR 1.8). Among the non-adherents at T12, 41.5% (80/193) discontinued by T3. The primary reason for non-adherence by T12 was physical complaints (13.0%; 95/721), mainly of gastrointestinal origin (7.9%; 57/721). (Figures 2 and 3) • Univariate (logistic/Cox) regression analyses

(p<0.15) identified gender, premedication pause, pre-treatments (≥ 2), depression, QoL, life/treatment satisfaction, fatigue, anxiety and nonverbal memory as putative predictors of non-adherence. (Table 3)

Table 1. Demographic baseline characteristics

Table 2. Development of clinical, behavioral and cognitive parameters during 12 months of DMF treatment

Variable (N=number of patients; SD=standard deviation; min=minimum; max=maximum)	ТО	T12
EDSS, N, median (min, max)	704, 2.0 (0.0, 7.5)	399, 2.0 (0.0, 6.5)
Al (Walking), N, median (min, max)	580, 0.0 (0.0, 8.0)	332, 0.0 (0.0, 8.0)
BDI, N, median (min, max)	668, 2.0 (0.0, 15.0)	388, 1.0 (0.0, 15.0)
EQ5D-VAS, N, mean (SD)	675, 73.7 (18.7)	376, 76.7 (18.0)
FSMC, N, mean (SD)	610, 53.7 (21.8)	373, 54.2 (22.7)
STAI-G-X1, N, mean (SD)	609, 39.7 (11.1)	362, 38.2 (11.3)
STAI-G-X2, N, mean (SD)	604, 40.1 (11.3)	348, 38.8 (11.4)
TSQM-9, N, mean (SD)	363, 45.9 (9.5)	373, 49.5 (7.8)
SDMT, N, mean (SD)	663, 49.0 (14.4)	349, 49.5 (13.7)
CVLT, N, mean (SD)	665, 57.4 (11.7)	356, 58.4 (12.0)
BVMT-R, N, mean (SD)	665, 25.2 (7.8)	353, 26.8 (7.2)
FLZ health, N, mean (SD)	605, 32.8 (8.9)	316, 35.1 (8.7)
FLZ work and career, N, mean (SD)	571, 36.2 (8.3)	313, 36.5 (8.6)
FLZ own self, N, mean (SD)	605, 37.7 (6.9)	324, 37.9 (7.0)
FLZ marriage and partnership, N, mean (SD)	512, 41.5 (7.7)	278, 41.1 (7.6)

BMI = Body Mass Index; BDI-FS = Beck Depression Inventory – Fast Screen; EQ5D-VAS = European Quality of Life Index, 5 dimensions – visual analogue scale; FLZ = Fragebogen zur Lebenszufriedenheit (Questions on Life Satisfaction); FSMC = Fatigue Scale for Motor and Cognitive Functions; STAI = State-Trait Anxiety Inventory BVMT = Brief Visuospatial Memory Test; TSQM = Treatment Satisfaction Questionnaire for Medication; EDSS = Expanded Disability Status Scale; AI = Ambulation Index; SDMT = Symbol Digit Modalities Test; CVLT = California Verbal Learning Test

Figure 1. German NTD centers collaborating in the study



treated with DMF (T12 results)

Variable	Hazard Ratio (Confidence Interval, 85% Wald conf. limits)"	Odds Ratio (Confidence Interval, 85% Wald conf. limits)	
Sex (female vs. male)	1.76 (1.35; 2.29)	1.95 (1.45; 2.63)	
Number of pretreatments (≥2 vs. none)	1.37 (1.06; 1.78)	1.47 (1.08; 2.00)	
BDI-FS	1.08 (1.04; 1.11)	1.08 (1.04; 1.13)	
BVMT Learning	1.06 (1.01; 1.11)	1.07 (1.01; 1.13)	
BMI	1.04 (1.02; 1.06)	1.04 (1.02; 1.07)	
STAI-G-X1	1.02 (1.01; 1.03)	1.02 (1.01; 1.03)	
STAI-G-X2	1.02 (1.01; 1.03)	1.02 (1.01; 1.03)	
Premedpause	1.01 (1.00; 1.01)	1.01 (1.00; 1.02)	
FSMC	1.01 (1.00; 1.02)	1.01 (1.01; 1.02)	
EQ5D-VAS	0.99 (0.99; 1.00)	0.99 (0.99; 1.00)	
FLZ Work & Career	0.98 (0.97; 1.00)	0.98 (0.97; 1.00)	
FLZ Own self	0.98 (0.96; 0.99)	0.97 (0.96; 0.99)	
BVMT Total Recall	0.98 (0.97; 1.00)	0.98 (0.96; 1.00)	
FLZ Health	0.97 (0.96; 0.99)	0.97 (0.96; 0.99)	
TSQM-9	0.96 (0.94; 0.97)	0.95 (0.93; 0.97)	
BVMT Trial 1	0.94 (0.90; 0.97)	0.92 (0.88; 0.96)	
Number of pretreatments (1 vs. none)	0.91 (0.71;1.18)	0.88 (0.66;1.19)	




Figure 2. Kaplan-Meier curve depicting gender-related non-adherence (male/female) in RRMS-patients treated with DMF (721 patients)

Table 3. Analysis of parameters probably affecting time to non-adherence (p < 0.15) in RRMS-patients

